MED12 and neoplasm: In BM‐LUAD 12, CSF ctDNA had a greater advantage in detecting a set of somatic alterations that occurred in BM including tumor suppressor gene mutations TP53 and RB1, and investigational targets CDK13 and MED12 (Fig. 5C).